Comprehensive analysis of UTI-Healthcare Fund - Direct (IDCW) (16210) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
UTI Asset Management Company Ltd
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
A comprehensive at-a-glance view of key mutual fund health indicators
Strong Returns
High Risk
Moderate Expenses
Equity Focused
Experienced Team
Average Quality
Showing 1Y NAV history
Performance across different time periods
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Recent performance momentum
Fund manager experience
Market exposure level
Historical performance consistency
Fund management costs
Risk-adjusted returns
Assets under management
Outperformance vs benchmark
This fund has outperformed its benchmark by 14.53% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 10.08% |
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 9.84% |
| Cipla Ltd | Pharmaceuticals | 5.48% |
| Cipla Ltd | Pharmaceuticals | 5.43% |
| Ajanta Pharma Ltd | Pharmaceuticals | 4.92% |
| Ajanta Pharma Ltd | Pharmaceuticals | 4.80% |
| Procter & Gamble Health Ltd | Pharmaceuticals | 4.30% |
| Lupin Ltd | Pharmaceuticals | 4.29% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 4.20% |
| Procter & Gamble Health Ltd | Pharmaceuticals | 4.13% |
Compare against Sectoral / Thematic category average
This comparison shows how the fund performs relative to the Sectoral / Thematic category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Sectoral / Thematic category
| Fund Name | NAV | 6M | 1Y | 3Y |
|---|---|---|---|---|
| Aditya Birla SL MNC Fund - Direct (G) | ₹1524.25 | 3.38% | 0.21% | 17.40% |
| Aditya Birla SL MNC Fund - (G) | ₹1370.22 | 3.04% | -0.47% | 16.56% |
| Nippon India Banking&Financial Services-Dir(Bonus) | ₹702.57 | 15.30% | 15.12% | 26.92% |
| Nippon India Banking&Financial Services-Dir(G) | ₹702.57 | 15.30% | 15.12% | 26.92% |
| Nippon India Banking&Financial Services (Bonus) | ₹643.19 | 14.82% | 14.17% | 25.88% |
| Nippon India Banking&Financial Services (G) | ₹643.19 | 14.82% | 14.17% | 25.88% |
| Nippon India Pharma Fund - Direct (Bonus) | ₹575.71 | -1.82% | 16.88% | 26.41% |
| Nippon India Pharma Fund - Direct (G) | ₹575.71 | -1.82% | 16.88% | 26.41% |
| Franklin India Technology Fund - Direct (G) | ₹575.22 | -4.25% | 7.83% | 25.35% |
| ICICI Pru FMCG Fund - Direct (G) | ₹523.66 | 1.39% | 0.04% | 13.50% |
A seasoned investment professional with over 13 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.